Insmed Incorporated is presenting data on their therapies for rare pulmonary conditions at the American Thoracic Society‘s (ATS) 2015 International Conference, which is currently underway and will wrap up on May 20th in Denver. The company is hosting six abstracts on ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung infections caused by Mycobacterium avium complex (MAC), and INS1009 for the treatment of pulmonary arterial hypertension (PAH).
During the poster session “Diagnosis and Management of Nontuberculous Mycobacteria Infections,” the company will present three abstracts on the liposomal amikacin-inhalated treatment ARIKAYCE, which is in late-stage development and expected to become a viable treatment for adults who suffer from NTM lung infections due to MAC. In addition, three other abstracts on the inhaled prodrug formulation of treprostinil (INS1009) for PAH will be presented during the “Preclinical Trials in Pulmonary Hypertension Models: Novel Targets and Delivery” poster session.
Insmed’s Presentations on ARIKAYCE for Nontuberculous Mycobacterial Lung Infections
ARIKAYCE was developed to extend amikacin delivery to the lungs, as well as decrease systemic exposure. It is an antibiotic amikacin based on advanced pulmonary liposome technology, administered one time per day via an optimized investigational eFlow Nebulizer System developed by PARI Pharma.
“Subgroup Analyses of Baseline Demographics and Efficacy in Patients with Refractory Nontuberculous Mycobacteria (NTM) Lung Infection Treated with Liposomal Amikacin for Inhalation (LAI)” is the first abstract to be presented by lead author K.L. Winthrop, MD, while J.A. Biller, MD, will address the “Efficacy of Liposomal Amikacin for Inhalation (LAI) in Achieving Nontuberculous Mycobacteria (NTM) Culture Negativity in Patients Whose Lung Infection is Refractory to Guideline-Based Therapy.”
The third abstract is entitled “Analysis of Functional Exercise Capacity (Via the Six-Minute Walk Test [6MWT]) and Culture Negativity in Patients with Nontuberculous Mycobacteria (NTM) Lung Infection Refractory to Guideline-Based Therapy Treated with Liposomal Amikacin for Inhalation (LAI)” and will be presented by S.J. Ruoss, MD. The presentations and abstracts to be hosted at the ATS conference can be accessed at the website of the event here.
Inmed’s Presentations on INS1009 for PAH
In addition to ARIKAYCE, Insmed will also be presenting on treprostinil, otherwise known as INS1009. INS1009 is Insmed’s lead product for improving the treatment of PAH by reducing the limitations of currently available inhaled prostacyclin therapies. The company has used its drug development platform and sustained-release formulation expertise in the creation of INS1009, which is expected to become a once-daily inhaled therapy able to decrease acute systemic effects and improve the symptoms of the chronic and life-threatening condition.
V. Malinin, PhD, will present the abstract “A 14-Day Assessment of the Tolerability and Pharmacokinetics (Pk) with a Nanoparticle Formulation of Hexadecyl-Treprostinil a Long-Acting Pulmonary Vasodilator In Rats,” while the study on “Prolonged Pharmacokinetic Profile of a Prodrug Lipid Nanoparticle Formulation of Treprostinil in Dogs,” will be presented by study author F.G. Leifer, PhD.
In addition, the abstract entitled “Effect of a Lipid Nanoparticle Prodrug Formulation of Treprostinil on the Cough Reflex in Guinea Pigs” will be presented by lead author R.W. Chapman, PhD.